Insider Transactions in Q3 2022 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$82,500
$66.0 P/Share
|
|
Sep 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Sep 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.25%
|
$756,000
$63.98 P/Share
|
|
Sep 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.89%
|
$37,000
$2.67 P/Share
|
|
Sep 08
2022
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
15,000
-5.87%
|
$975,000
$65.0 P/Share
|
|
Sep 06
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-10.44%
|
$300,000
$60.38 P/Share
|
|
Sep 06
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.45%
|
$75,000
$15.09 P/Share
|
|
Sep 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.33%
|
$150,000
$60.3 P/Share
|
|
Aug 30
2022
|
James George Chopas VP/Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-2.92%
|
$32,364
$58.84 P/Share
|
|
Aug 25
2022
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,306
+3.2%
|
$55,978
$13.19 P/Share
|
|
Aug 17
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.6%
|
$345,000
$69.5 P/Share
|
|
Aug 17
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.74%
|
$75,000
$15.52 P/Share
|
|
Aug 16
2022
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,394
+16.76%
|
$355,516
$14.0 P/Share
|
|
Aug 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$83,750
$67.21 P/Share
|
|
Aug 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Aug 15
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,500
-22.56%
|
$862,500
$69.0 P/Share
|
|
Aug 15
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+18.41%
|
$187,500
$15.09 P/Share
|
|
Aug 11
2022
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
30,000
-10.5%
|
$1,950,000
$65.63 P/Share
|
|
Aug 11
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.6%
|
$335,000
$67.0 P/Share
|
|
Aug 11
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.74%
|
$75,000
$15.52 P/Share
|
|
Aug 11
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,500
-22.56%
|
$837,500
$67.0 P/Share
|
|
Aug 11
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+18.41%
|
$187,500
$15.09 P/Share
|
|
Aug 08
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.6%
|
$320,000
$64.5 P/Share
|
|
Aug 08
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.74%
|
$75,000
$15.52 P/Share
|
|
Aug 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.25%
|
$744,000
$62.5 P/Share
|
|
Aug 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.9%
|
$37,000
$2.67 P/Share
|
|
Aug 08
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,500
-22.56%
|
$812,500
$65.0 P/Share
|
|
Aug 08
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+18.41%
|
$187,500
$15.09 P/Share
|
|
Aug 04
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
10,000
-13.67%
|
$600,000
$60.75 P/Share
|
|
Aug 04
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+20.3%
|
$150,000
$15.52 P/Share
|
|
Aug 03
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+10.44%
|
$75,000
$15.09 P/Share
|
|
Aug 03
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-11.65%
|
$280,000
$56.43 P/Share
|
|
Aug 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.28%
|
$137,500
$55.99 P/Share
|
|
Jul 27
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.6%
|
$285,000
$57.0 P/Share
|
|
Jul 27
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.74%
|
$75,000
$15.52 P/Share
|
|
Jul 21
2022
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,606
+8.71%
|
$134,484
$14.0 P/Share
|
|
Jul 19
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.6%
|
$280,000
$56.42 P/Share
|
|
Jul 19
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.74%
|
$75,000
$15.52 P/Share
|
|
Jul 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$57,500
$46.33 P/Share
|
|
Jul 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Jul 11
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-10.44%
|
$240,000
$48.42 P/Share
|
|
Jul 11
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.45%
|
$75,000
$15.09 P/Share
|
|
Jul 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.26%
|
$564,000
$47.95 P/Share
|
|
Jul 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+0.97%
|
$37,000
$2.67 P/Share
|